Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
Ana I. Robles(National Cancer Institute), Oluf Dimitri Røe(Norwegian University of Science and Technology), Robert A. Anders(Johns Hopkins University), Katalin Dobra(Karolinska University Hospital), Nagahiro Minato(Kyoto University), Michaela B. Kirschner(University Hospital Zurich), Mogens Vyberg(Aalborg University Hospital), Hans E. Krokan(Norwegian University of Science and Technology), Jenette Creaney(Asbestos Diseases Research Institute), Ioannis Tsamardinos(University of Crete), Karina Standahl Olsen(UiT The Arctic University of Norway), Vassilis Georgoulias(Hellenic Oncology Research Group), Pål Sætrom(Norwegian University of Science and Technology), Jianwei Zhou(Second Affiliated Hospital of Zhejiang University), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Vassiliki A. Papadimitrakopoulou(Pfizer (United States)), Boye Schnack Nielsen(University of Southern Denmark), Dana W.Y. Tsui(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
|Molecular Cell|2012|3.7k